Finally, an unusual effect of simultaneous targeting of the RAS/RAF/MEK/ERK pathway molecules was described by Baudy et al, which observed that co-treatment of metastatic melanoma cells with cobimetinib (a MEK inhibitor also indicated as GDC-0973) and vemurafenib resulted in reduction of the fluorodeoxyglucose (FDG) uptake, associated with lower levels of glucose transporter (GLUT-1) at the cellular membrane of BRAFV600E cells both sensitive and resistant to vemurafenib. This evidence concerns the gene MAP2K7 and metastatic melanoma.